Here are five developments in orthobiologics since Sept. 5.
1. Lenoss Medical’s OsteoPearl biologic allograft for spine earned two new U.S. patents and one European patent.
2. Keensight Capital, a private equity manager, has acquired a majority stake in regenerative medtech company Isto Biologics from Thompson Street Capital Partners.
3. The American Academy of Orthopaedic Surgeons’ updated rotator cuff guideline strongly recommends the use of biologic implants during repair — a move that could reshape practice patterns and patient access.
4. Researchers at Columbia-based University of Missouri are developing bioactive materials to replace metal rods and screws traditionally used in spinal fusion surgeries.
5. Kuros Biosciences’ released its MagnetOS minimally invasive spine delivery system in a full commercial launch.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
